Jacob Funds, a mutual fund company, released its first-quarter 2026 investor letter. A copy of the letter can be downloaded here. The recent quarter began against the backdrop of the war in the Middle East and concerns about AI disruption in the tech space. However, these concerns eased, leading investors to focus more on AI winners and losers. Despite volatility, the emergence of AI is seen as a potential catalyst for business and economic innovation, similar to the late 1990s dot-com boom. This is happening more slowly than expected, but signs of increased activity suggest broader AI adoption is coming. The firm is optimistic about the portfolio adjustments made earlier this year as agentic AI becomes widely adopted. Please review the Fund’s top five holdings to gain insights into their key selections for 2026.
In its April 2026 investor letter, Jacob Funds highlighted Kyverna Therapeutics, Inc. (NASDAQ:KYTX). Kyverna Therapeutics, Inc. (NASDAQ:KYTX) is a late-stage biopharmaceutical company that focuses on developing cell therapies for patients with autoimmune diseases. On July 8, 2026, Kyverna Therapeutics, Inc. (NASDAQ:KYTX) closed at $9.91 per share, reflecting a market capitalization of $602.48 million. Kyverna Therapeutics, Inc. (NASDAQ:KYTX) posted a one-month return of 25.92%, while its shares gained 177.59% over the past 52 weeks.
Jacob Funds stated the following regarding Kyverna Therapeutics, Inc. (NASDAQ:KYTX) in its April 2026 investor update:
“The Jacob Discovery Fund also added a position in Securitize in the quarter as well as a new position in Kyverna Therapeutics, Inc. (NASDAQ:KYTX). Kyverna is a small biotech company developing cell therapies that aim to “reset” the immune system in severe autoimmune diseases. Its lead opportunity is in stiff person syndrome, a rare and debilitating neurologic disease with no approved treatment, where early patient data showed meaningful improvement in symptoms and daily function for some patients. Kyverna, along with Fund holdings Cabaletta Bio and Cartesian Therapeutics, are all trying to prove out this approach, which could potentially apply to larger autoimmune markets, including myasthenia gravis and multiple sclerosis. While challenges to a successful commercialization remain, we like the chances that these next-generation CAR-T programs will prove successful in several autoimmune diseases and want to have broad exposure to the opportunity. Kyverna’s stiff person syndrome drug may be the first of its kind to reach FDA approval, and like with Cabaletta and Cartesian, we believe, its market valuation gives scant for both its near-term prospects as well as the broader autoimmune platform potential.”
Kyverna Therapeutics, Inc. (NASDAQ:KYTX) is not on our list of 40 Most Popular Stocks Among Hedge Funds Heading Into 2026. According to our database, 27 hedge fund portfolios held Kyverna Therapeutics, Inc. (NASDAQ:KYTX) at the end of the first quarter, up from 23 in the previous quarter. While we acknowledge the risk and potential of Kyverna Therapeutics, Inc. (NASDAQ:KYTX) as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than Kyverna Therapeutics, Inc. (NASDAQ:KYTX) and that has 10,000% upside potential, check out our report about this cheapest AI stock.
In addition, please check out our hedge fund investor letters Q1 2026 page for more investor letters from hedge funds and other leading investors.
READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years.
Disclosure: None. This article is originally published at Insider Monkey.
